NTLA · Company research
Intellia Therapeutics, Inc (NTLA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now | Four biotech companies with advanced drug pipelines present potential investment opportunities as their experimental treatments progress through late-stage development and regulatory review. BridgeBio Pharma has three drug candidates under FDA review with decisions expected through May 2027. Intellia Therapeutics' gene-editing therapy lonvo-z showed 87% reduction in hereditary angioedema attacks. Biogen expects pivotal study results through 2027, while Viking Therapeutics advances obesity treatments in phase III trials. Success depends on regulatory approvals, clinical efficacy, and competitive market positioning. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | bullish | 0.75 | 1 |
| Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance - Yahoo Finance | Intellia Therapeutics (NTLA) Stock Looks Overvalued As Launch Preparations Advance Yahoo Finance | View source ↗ | Yahoo Finance | Oct 18, 2026 | neutral | 0 | 0.6 |
| NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits | NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI | NTLA Stock News Today | Earnings, Events & Price Alerts Intellectia AI | View source ↗ | Intellectia AI | Oct 14, 2026 | neutral | 0 | 0.6 |
| More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits | More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Nasdaq, S&P 500 Futures Cheer Iran Breakthrough, Crude Slides: Why SPCX, NVDA, RKLB, ASTS, RCAT, NTLA Are Keeping Traders Hooked - Stocktwits | Nasdaq, S&P 500 Futures Cheer Iran Breakthrough, Crude Slides: Why SPCX, NVDA, RKLB, ASTS, RCAT, NTLA Are Keeping Traders Hooked Stocktwits | View source ↗ | Stocktwits | Oct 12, 2026 | neutral | 0 | 0.6 |
| CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? - Stocktwits | CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? Stocktwits | View source ↗ | Stocktwits | Oct 11, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada | Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? - StockInvest.us | Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? StockInvest.us | View source ↗ | StockInvest.us | Oct 9, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? | Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? | Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? - Yahoo Finance | Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| To cover taxes, an Intellia Therapeutics (NTLA) officer sells 1,864 shares in a mandatory sale. - Stock Titan | To cover taxes, an Intellia Therapeutics (NTLA) officer sells 1,864 shares in a mandatory sale. Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| Officer Eliana Clark proposes selling 57,750 Intellia Therapeutics (Nasdaq: NTLA) shares. - Stock Titan | Officer Eliana Clark proposes selling 57,750 Intellia Therapeutics (Nasdaq: NTLA) shares. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics Stock Short Interest Rises to 41.97% - Quiver Quantitative | Intellia Therapeutics Stock Short Interest Rises to 41.97% Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 25, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy - Yahoo Finance | Intellia Therapeutics (NTLA) Stock Gets FDA Priority Review For Lonvo Z Gene Editing Therapy Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics (NTLA) CEO sells shares around $13 - Stock Titan | Intellia Therapeutics (NTLA) CEO sells shares around $13 Stock Titan | View source ↗ | Stock Titan | Aug 24, 2026 | neutral | 0 | 0.6 |
| Why Is NTLA Stock Jumping 5% Premarket Today? - Stocktwits | Why Is NTLA Stock Jumping 5% Premarket Today? Stocktwits | View source ↗ | Stocktwits | Jun 15, 2026 | neutral | 0 | 0.6 |
| Intellia Therapeutics Announces Proposed Public Offering of Common Stock - Intellia Therapeutics | Intellia Therapeutics Announces Proposed Public Offering of Common Stock Intellia Therapeutics | View source ↗ | Intellia Therapeutics | Apr 27, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.